Tiotropium reduces clinically important deterioration in patients with mild-to-moderate chronic obstructive pulmonary disease : A post hoc analysis of the Tie-COPD study
Copyright © 2024 Elsevier Ltd. All rights reserved..
BACKGROUND: Clinically important deterioration (CID) is a composite endpoint used to holistically assess the complex progression of chronic obstructive pulmonary disease (COPD). Tiotropium improves lung function and reduces the rate of COPD exacerbations in patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate). However, whether tiotropium reduces CID risk in patients with mild-to-moderate COPD remains unclear.
METHODS: This was a post hoc analysis of the 24-month Tie-COPD study comparing 18 μg tiotropium with placebo in patients with mild-to-moderate COPD. CID was defined as a decrease of ≥100 mL in trough forced expiratory volume in 1 s, an increase of ≥2 unit in COPD Assessment Test (CAT) score, or moderate-to-severe exacerbation. The time to the first occurrence of one of these events was recorded as the time to the first CID. Subgroup analyses were conducted among patients stratified by CAT score, modified Medical Research Council (mMRC) dyspnea score, and GOLD stage at baseline.
RESULTS: Of the 841 randomized patients, 771 were included in the full analysis set. Overall, 643 patients (83.4 %) experienced at least one CID event. Tiotropium significantly reduced the CID risk and delayed the time to first CID compared with placebo (adjusted hazard ratio = 0.58, 95 % confidence interval = 0.49-0.68, P < 0.001). Significant reductions in CID risk were also observed in various subgroups, including patients with a CAT score <10, mMRC score <2, and mild COPD.
CONCLUSIONS: Tiotropium reduced CID risk in patients with mild-to-moderate COPD, even in patients with fewer respiratory symptoms or mild disease, which highlights tiotropium's effectiveness in treating COPD patients with mild disease.
TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov (Tie-COPD, NCT01455129).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:222 |
|---|---|
| Enthalten in: |
Respiratory medicine - 222(2024) vom: 05. Feb., Seite 107527 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Fan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bronchodilator Agents |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT01455129 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmed.2024.107527 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366898795 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366898795 | ||
| 003 | DE-627 | ||
| 005 | 20240206232110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rmed.2024.107527 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM366898795 | ||
| 035 | |a (NLM)38199288 | ||
| 035 | |a (PII)S0954-6111(24)00001-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Fan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tiotropium reduces clinically important deterioration in patients with mild-to-moderate chronic obstructive pulmonary disease |b A post hoc analysis of the Tie-COPD study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01455129 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Clinically important deterioration (CID) is a composite endpoint used to holistically assess the complex progression of chronic obstructive pulmonary disease (COPD). Tiotropium improves lung function and reduces the rate of COPD exacerbations in patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate). However, whether tiotropium reduces CID risk in patients with mild-to-moderate COPD remains unclear | ||
| 520 | |a METHODS: This was a post hoc analysis of the 24-month Tie-COPD study comparing 18 μg tiotropium with placebo in patients with mild-to-moderate COPD. CID was defined as a decrease of ≥100 mL in trough forced expiratory volume in 1 s, an increase of ≥2 unit in COPD Assessment Test (CAT) score, or moderate-to-severe exacerbation. The time to the first occurrence of one of these events was recorded as the time to the first CID. Subgroup analyses were conducted among patients stratified by CAT score, modified Medical Research Council (mMRC) dyspnea score, and GOLD stage at baseline | ||
| 520 | |a RESULTS: Of the 841 randomized patients, 771 were included in the full analysis set. Overall, 643 patients (83.4 %) experienced at least one CID event. Tiotropium significantly reduced the CID risk and delayed the time to first CID compared with placebo (adjusted hazard ratio = 0.58, 95 % confidence interval = 0.49-0.68, P < 0.001). Significant reductions in CID risk were also observed in various subgroups, including patients with a CAT score <10, mMRC score <2, and mild COPD | ||
| 520 | |a CONCLUSIONS: Tiotropium reduced CID risk in patients with mild-to-moderate COPD, even in patients with fewer respiratory symptoms or mild disease, which highlights tiotropium's effectiveness in treating COPD patients with mild disease | ||
| 520 | |a TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov (Tie-COPD, NCT01455129) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 650 | 4 | |a Clinically important deterioration | |
| 650 | 4 | |a Mild-to-moderate | |
| 650 | 4 | |a Tiotropium | |
| 650 | 7 | |a Tiotropium Bromide |2 NLM | |
| 650 | 7 | |a XX112XZP0J |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 700 | 1 | |a Dai, Cuiqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yumin |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Zhishan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zihui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaochen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shuyun |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Weijie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Nanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Ran, Pixin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory medicine |d 1993 |g 222(2024) vom: 05. Feb., Seite 107527 |w (DE-627)NLM012605247 |x 1532-3064 |7 nnns |
| 773 | 1 | 8 | |g volume:222 |g year:2024 |g day:05 |g month:02 |g pages:107527 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmed.2024.107527 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 222 |j 2024 |b 05 |c 02 |h 107527 | ||